VKTX Viking Therapeutics Loading...

Loading chart...
Top Calls
Feed
All Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
Loading...
0 selected
All Content✓
Source feeds
Buzzberg's Top 50 ✓
All directions✓
▲ Long✓
▼ Short✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
04:37
May 26
__con_
Buy VKTX as part of an active short-term trade portfolio; author sets explicit upside price target of $35, indicating a committed long position with defined exit.
VKTX
MED
13:09
Apr 27
A May MD Biotech investor
Adam May boasts a strong short-selling track record with past wins on NTLA, HIMS, VKTX, and IOVA, and expresses a forward-looking bearish view on ORKA.
VKTX
HIGH
22:11
Apr 26
__con_
Explicit portfolio list: 'If I had to hold 10 stocks for 2026' — first-person commitment to holding $VKTX.
VKTX
MED
15:08
Apr 21
__con_
Speaker found niche peptide stock $VKTX with detailed thesis: dual GLP-1/GIP agonist (sub+oral) attacking $100B+ obesity market, both VANQUISH-1 and VANQUISH-2 Phase 3 trials fully enrolled.
VKTX 1ST
MED

About VKTX Analyst Coverage

Buzzberg tracks VKTX (Viking Therapeutics) across 2 sources. 3 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (75%). 4 total trade ideas tracked.